

# Phase I trial MM-120-102

<b>Submission date</b> 17/05/2024	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 21/05/2024	<b>Overall study status</b> Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 13/01/2026	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

## Contact information

### Type(s)

Public, Scientific, Principal investigator

### Contact name

Dr David Gregory

### Contact details

11 Tiger Court, Kings Drive Prescot  
Liverpool  
United Kingdom  
L34 1BH  
+44 (0)1514824700  
davidgregory@macplc.com

### Type(s)

Scientific

### Contact name

None Jo Brady

### Contact details

Senior Consultant  
DLRC Regulatory Consultancy  
Suite 201, The Nexus Building, Broadway  
Letchworth Garden City  
United Kingdom  
Herts SG6 3TA

+44 01462 372472  
Jo.Brady@dlrcgroup.com

## **Additional identifiers**

**Clinical Trials Information System (CTIS)**  
Nil known

**Integrated Research Application System (IRAS)**  
1009246

**ClinicalTrials.gov (NCT)**  
Nil known

**Protocol serial number**  
IRAS 1009246

## **Study information**

**Scientific Title**  
Phase I trial MM-120-102 [The full scientific title will be published within 30 months after the end of the trial]

**Study objectives**  
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Ethics approval required**  
Ethics approval required

**Ethics approval(s)**  
approved 22/03/2024, Wales Research Ethics Committee 1 (Health and Care Research Wales, Castlebridge 4, 15-19 Cowbridge Road, Cardiff, CF11 9AB, United Kingdom; +44 (0)2922940912; wales.rec1@wales.nhs.uk), ref: 24/WA/0003 and CTA 57953/0003/001-0001

**Study design**  
Phase I study in 32 healthy volunteers

**Primary study design**  
Interventional

**Study type(s)**  
Other

**Health condition(s) or problem(s) studied**  
Healthy volunteers

**Interventions**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Intervention Type**

Drug

### **Phase**

Phase I

### **Drug/device/biological/vaccine name(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Primary outcome(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Key secondary outcome(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Completion date**

29/08/2024

## **Eligibility**

### **Key inclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Participant type(s)**

Healthy volunteer

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Sex**

All

### **Total final enrolment**

0

## **Key exclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

## **Date of first enrolment**

08/05/2024

## **Date of final enrolment**

17/06/2024

## **Locations**

### **Countries of recruitment**

United Kingdom

England

### **Study participating centre**

#### **MAC Clinical Research Liverpool**

11 Tiger Court  
King's Business Park  
Liverpool  
England  
L34 1BH

### **Study participating centre**

#### **MAC Clinical Research Manchester**

Citylabs 1.0  
Nelson St  
Manchester  
England  
M13 9NQ

## **Sponsor information**

### **Organisation**

Mind Medicine Inc.

## **Funder(s)**

**Funder type**

Industry

**Funder Name**

Mind Medicine Inc.

**Results and Publications****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not expected to be made available